These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32116806)

  • 41. Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study.
    Jones GM; Nock MK
    Sci Rep; 2022 Feb; 12(1):2574. PubMed ID: 35173246
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress.
    Ross S
    Int Rev Psychiatry; 2018 Aug; 30(4):317-330. PubMed ID: 30102082
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports.
    Nayak SM; Gukasyan N; Barrett FS; Erowid E; Erowid F; Griffiths RR
    Pharmacopsychiatry; 2021 Sep; 54(5):240-245. PubMed ID: 34348413
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Past and Future of Psychedelic Science: An Introduction to This Issue.
    Doblin RE; Christiansen M; Jerome L; Burge B
    J Psychoactive Drugs; 2019; 51(2):93-97. PubMed ID: 31132970
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Psychedelics and music: neuroscience and therapeutic implications.
    Barrett FS; Preller KH; Kaelen M
    Int Rev Psychiatry; 2018 Aug; 30(4):350-362. PubMed ID: 30240282
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Psychedelic use and intimate partner violence: The role of emotion regulation.
    Thiessen MS; Walsh Z; Bird BM; Lafrance A
    J Psychopharmacol; 2018 Jul; 32(7):749-755. PubMed ID: 29807492
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Self-Entropic Broadening Theory: Toward a New Understanding of Self and Behavior Change Informed by Psychedelics and Psychosis.
    Dourron HM; Strauss C; Hendricks PS
    Pharmacol Rev; 2022 Oct; 74(4):982-1027. PubMed ID: 36113878
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey.
    Garcia-Romeu A; Davis AK; Erowid E; Erowid F; Griffiths RR; Johnson MW
    Front Psychiatry; 2019; 10():955. PubMed ID: 32038317
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
    Rosenbaum D; Weissman C; Anderson T; Petranker R; Dinh-Williams LA; Hui K; Hapke E
    J Psychopharmacol; 2020 Jun; 34(6):612-622. PubMed ID: 32108529
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications.
    Kraehenmann R
    Curr Neuropharmacol; 2017; 15(7):1032-1042. PubMed ID: 28625125
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders.
    Mertens LJ; Preller KH
    Pharmacopsychiatry; 2021 Jul; 54(4):176-190. PubMed ID: 33472250
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice.
    Gorman I; Nielson EM; Molinar A; Cassidy K; Sabbagh J
    Front Psychol; 2021; 12():645246. PubMed ID: 33796055
    [TBL] [Abstract][Full Text] [Related]  

  • 53. "Research chemicals": tryptamine and phenethylamine use among high-risk youth.
    Sanders B; Lankenau SE; Bloom JJ; Hathazi D
    Subst Use Misuse; 2008; 43(3-4):389-402. PubMed ID: 18365939
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chemistry and Structure-Activity Relationships of Psychedelics.
    Nichols DE
    Curr Top Behav Neurosci; 2018; 36():1-43. PubMed ID: 28401524
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs.
    Yaden DB; Berghella AP; Regier PS; Garcia-Romeu A; Johnson MW; Hendricks PS
    Int J Drug Policy; 2021 Dec; 98():103380. PubMed ID: 34329952
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The association of psychedelic use and opioid use disorders among illicit users in the United States.
    Pisano VD; Putnam NP; Kramer HM; Franciotti KJ; Halpern JH; Holden SC
    J Psychopharmacol; 2017 May; 31(5):606-613. PubMed ID: 28196428
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Classic psychedelics do not affect T cell and monocyte immune responses.
    Rudin D; Areesanan A; Liechti ME; Gründemann C
    Front Psychiatry; 2023; 14():1042440. PubMed ID: 36741125
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study.
    Révész D; Ona G; Rossi GN; Rocha JM; Dos Santos RG; Hallak JEC; Alcázar-Córcoles MÁ; Bouso JC
    Front Psychiatry; 2021; 12():687546. PubMed ID: 34220590
    [No Abstract]   [Full Text] [Related]  

  • 59. Well-being, problematic alcohol consumption and acute subjective drug effects in past-year ayahuasca users: a large, international, self-selecting online survey.
    Lawn W; Hallak JE; Crippa JA; Dos Santos R; Porffy L; Barratt MJ; Ferris JA; Winstock AR; Morgan CJA
    Sci Rep; 2017 Nov; 7(1):15201. PubMed ID: 29123145
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interest in receiving psychedelic-assisted therapy among marginalized women: Implications and findings from a community-based study in Canada.
    Argento E; Goldenberg S; Deering K; Lavalley J; Braschel M; Bingham B; Shannon K
    Drug Alcohol Depend Rep; 2022 Jun; 3():100044. PubMed ID: 36845985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.